Encrypted RNA™
target-activated immunity



 
 

Autonomous Therapeutics

is pioneering a new class of RNA (encRNA) to develop first-in-class medicines that are target-activated and variant-proof from influenza to cancers.

 

Press & Media

Featured
Autonomous Therapeutics and Mink Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
Autonomous CEO, Dr. Ariel Weinberger, serves on keynote panel at World Vaccine & Immunotherapy Congress
Autonomous CEO, Dr. Ariel Weinberger, gives plenary presentation at NIH Synthetic Biology Consortium Meeting
Autonomous Therapeutics wins $1 million Blue Knight™ QuickFire Challenge
Keynote Panel @ RNA Leaders USA Congress
Op-Ed in BioCentury: The urgent need for variant-proof therapeutics

 

 
 

Contact

Autonomous Therapeutics, Inc.
1530 East Jefferson Street
Rockville, MD 20852